Drug intelligence / Profile preview

PF-08046044

Development stage: Discontinued
Lead developer: Pfizer
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

PF-08046044 (also known as SGN-35C) is an investigational antibody-drug conjugate (ADC) under development by Pfizer for the treatment of various lymphomas, including anaplastic large cell lymphoma (ALCL), Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), and diffuse large B cell lymphoma (DLBCL). The drug consists of a next-generation CD30-directed monoclonal antibody conjugated to a novel topoisomerase I inhibitor payload via a glucuronide linker. CD30 is highly expressed in many B-cell and T-cell lymphomas but has limited expression in normal tissues. PF-08046044 is administered intravenously and is currently in Phase 1 clinical trials for ALCL and other lymphomas.

Targets

TOP1 (DNA Topoisomerase I)CD30 (CD30 antigen)

Beyond the preview

Go deeper on PF-08046044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-08046044.

Explore the full profile